Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

carfilzomid

Home/Tag:carfilzomid
18 09, 2010

The MMRF & IMF Need To Remember Who They Represent–The Patient–Not The Drug Companies

Tags: , , , , , , , , |6 Comments

I had already written part of today's article. But after reading this comment from Nick in California, defending the MMRF, I decided to go in a different direction:Nick said... Hmm...not sure what to make of this, to be honest with you! :)While the MMRF doesn't necessarily agree with the approach that my oncologist takes, I

11 09, 2010

Sale Of Carfilzomib Rights In Japan Provides Cash For Continued Research By Onyx Pharmaceuticals

Tags: , , , |2 Comments

I'm getting to this story a few days late, but that doesn't mean it isn't important. Business news does directly affect multiple myeloma patients. This sale provides Onyx Pharmaceuticals, makers of the new proteasome inhibitor carfilzomib, a much needed cash infusion to continue research and fund more clinical studies:Onyx licenses to Ono Japanese rights to

5 06, 2010

Follow-Up Analysis Of Onyx Pharmaceuticals’ Carfilzomib 004 Study Against Refractory Multiple Myeloma

Tags: , , , |1 Comment

Onyx Pharmaceuticals' Carfilzomib Highlights First Day Of ASCO Meetings In ChicagoFlaunting an impressive 55% success rate in previously treated multiple myeloma patients, Onyx Pharmaceuticals revealed the results of their ongoing Phase 2 clinical carfilzomib study, 004 at the American Society of Clinical Oncology (ASCO) meetings here in Chicago.Carfilzomib is a selective, next-generation proteasome inhibitor, similar

11 10, 2009

Carfilzomid Better Than Velcade?

Tags: , , , , |0 Comments

Did you all see this?Preliminary results from an ongoing Phase 1 clinical trial indicate that carfilzomib, a new proteasome inhibitor, has significant therapeutic results in patients with relapsed myeloma. The Multiple Myeloma Research Consortium (MMRC) reported the results at the Joint ECCO 15-34th ESMO Multidisciplinary Congress, which was held in Berlin from September 20 to